Geroprotectors Reviewed: How Rapamycin, Metformin and Senolytics Target Aging
A comprehensive 2026 review maps the mechanisms and clinical potential of leading anti-aging compounds across five major geroprotector classes.
Summary
Russian researchers from the Institute of Biochemistry and Genetics in Ufa have published a sweeping review of geroprotectors — compounds designed to slow biological aging and extend healthspan. The review catalogues five major classes: senolytics, senostatics, calorie restriction mimetics, antioxidants, and hormetic agents. Highlighted compounds include the dasatinib-quercetin combination, rapamycin, metformin, coenzyme Q10, sulforaphane, and curcumin. Preclinical animal studies consistently show these agents can extend lifespan and improve organ function. Early clinical data remain limited but encouraging. The authors call for expanded human trials to establish safety, efficacy, and real-world applicability, framing geroprotectors as a promising frontier in combating age-related chronic disease.
Detailed Summary
Global aging demographics are intensifying the urgency of finding interventions that address not just lifespan but healthspan — the period of life free from debilitating chronic disease. As cells accumulate molecular and structural damage over time, multi-morbidity becomes the norm, complicating treatment and eroding quality of life. Geroprotectors represent a targeted pharmacological strategy aimed directly at the root biological mechanisms of aging rather than individual diseases.
This 2026 narrative review by Petintseva and Erdman systematically surveys the five principal categories of geroprotectors. Senolytics (e.g., dasatinib + quercetin) selectively eliminate senescent cells; senostatics suppress the harmful secretory phenotype of those cells. Calorie restriction mimetics like rapamycin and metformin activate nutrient-sensing pathways including mTOR inhibition and AMPK activation. Antioxidants such as coenzyme Q10 counteract mitochondrial oxidative stress, while hormetic agents like sulforaphane and curcumin trigger adaptive stress-response pathways.
Preclinical evidence across multiple animal models demonstrates that these compounds can meaningfully extend lifespan and preserve physiological function in multiple organ systems. The dasatinib-quercetin combination in particular has shown measurable reductions in senescent cell burden. Rapamycin's mTOR inhibition has produced some of the most robust lifespan extensions in mouse models to date.
Clinically, data are still early-stage but point in a promising direction. Metformin's association with reduced all-cause mortality in diabetic cohorts has spurred the landmark TAME trial. Senolytic pilot studies in humans have reported functional improvements in small samples.
The authors note that translation from animal to human remains the central challenge, with questions around dosing, long-term safety, and biomarker validation still unresolved. They advocate for rigorous, well-powered human trials to move the field forward.
Key Findings
- Five geroprotector classes identified: senolytics, senostatics, CR mimetics, antioxidants, and hormetic agents.
- Dasatinib + quercetin combination reduces senescent cell burden in preclinical and early human studies.
- Rapamycin via mTOR inhibition produces robust lifespan extension in multiple animal models.
- Metformin and rapamycin mimic caloric restriction by modulating AMPK and mTOR nutrient-sensing pathways.
- Clinical data remain limited in scale but consistently report encouraging safety and efficacy signals.
Methodology
This is a narrative review article published in Advances in Gerontology (2026), synthesizing findings from preclinical animal studies and available clinical trials on geroprotective compounds. No original experimental data were generated; conclusions are drawn from the existing published literature. The review was authored by researchers affiliated with the Institute of Biochemistry and Genetics, Ufa Federal Research Centre of RAS, Russia.
Study Limitations
As a narrative review based only on an abstract, the specific studies cited and the depth of critical appraisal cannot be fully assessed. The article is published in Russian, limiting accessibility for non-Russian-speaking audiences. Clinical evidence base for most geroprotectors remains small, heterogeneous, and insufficiently powered to support definitive therapeutic recommendations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: